Dranenko N. Clinical features and medicamentous treatment of stable angina pectoris and unstable angina pectoris in hypervasopressinemia.

The aim of the study was to determine features of arginin-vasopressin (AVP) secretion in patients suffering from stable and unstable angina pectoris associated with congestive heart failure, to analyze connection between serum AVP level and von Willebrand factor activity and to estimate possibility of angiotensin-coverting enzime (ACE) inhibitor quinapril and angiotensin receptors blocker (ARB) valsartan to decrease hypervasopressinemia. It was established that AVP level in coronary artery disease (CAD) patients was significantly higher than in healthy people. There was no significantly difference of AVP serum concentration between patients with stable or unstable angina pectoris. AVP level depends on functional class of stable angina pectoris, stage of congestive heart failure, presence of postinfarction cardiosclerosis. Correlative analysis has showed a reverse tie between serum AVP concentration and ejection fraction value. A direct connection was determined between AVP concentration and serum activity of von Willebrand factor in patients with sta-ble and unstable angina pectoris. Expedience of ACE inhibitor quinapril and ARB valsartan administration was grounded in treatment of stable angina pectoris patients with hypervasopressinemia.